Diverse mechanisms of AKT pathway activation in human malignancy.

AKT/PKB (Protein Kinase B) are central proteins mediating signals from receptor tyrosine kinases and phosphatidylinositol 3-kinase. AKT kinases are involved in a number of important cellular processes including cell proliferation and survival, cell size in response to nutrient availability, tumor invasion/metastasis, and angiogenesis.Various components of the AKT signaling pathway are encoded by tumor suppressor genes and oncogenes whose loss or activation, respectively, plays an important role in tumorigenesis. The growing body of evidence connecting deregulated AKT signaling with sporadic human cancers and inherited cancer predisposition syndromes is discussed. We also highlight new findings regarding the involvement of activating mutations of AKT1, AKT2, and AKT3 in somatic overgrowth disorders: Proteus syndrome, hypoglycemia with hypertrophy, and hemimegalencephaly, respectively. In addition, we review recent literature documenting the various ways the AKT signaling pathway is activated in human cancers and consequences for molecularly targeted therapies.

[1]  H. Aburatani,et al.  The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas , 2009, British Journal of Cancer.

[2]  H. Gelderblom,et al.  Small Molecule Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: An Update of Recent Developments , 2007, Annals of Surgical Oncology.

[3]  B. Karlan,et al.  Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. , 2003, Cancer research.

[4]  J. Cheng,et al.  Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[5]  J. Testa,et al.  Activation of AKT kinases in cancer: implications for therapeutic targeting. , 2005, Advances in cancer research.

[6]  A. Marchetti,et al.  AKT1E17K in human solid tumours , 2008, Oncogene.

[7]  M. Kaminski,et al.  Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14. , 2008, Cancer research.

[8]  C. Eng,et al.  PTEN hamartoma tumor syndrome: An overview , 2009, Genetics in Medicine.

[9]  Y. Hayashizaki,et al.  Isolation of DNA sequences amplified at chromosome 19q13.1-q13.2 including the AKT2 locus in human pancreatic cancer. , 1996, Biochemical and biophysical research communications.

[10]  Taiping Zhang,et al.  Circulating microRNAs in cancer: diagnostic and prognostic significance , 2012, Expert review of anticancer therapy.

[11]  Xiaohong Song,et al.  Implication of the Akt2/survivin pathway as a critical target in paclitaxel treatment in human ovarian cancer cells. , 2009, Cancer letters.

[12]  R. Cardiff,et al.  Simultaneous haploinsufficiency of Pten and Trp53 tumor suppressor genes accelerates tumorigenesis in a mouse model of prostate cancer. , 2009, Differentiation; research in biological diversity.

[13]  I. Shih,et al.  Amplicon profiles in ovarian serous carcinomas , 2007, International journal of cancer.

[14]  Jamie K Teer,et al.  A mosaic activating mutation in AKT1 associated with the Proteus syndrome. , 2011, The New England journal of medicine.

[15]  J. Schlessinger,et al.  Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[16]  M. Sanchez-Cespedes.  A role for LKB1 gene in human cancer beyond the Peutz–Jeghers syndrome , 2007, Oncogene.

[17]  M. Cohen,et al.  Proteus syndrome: An update , 2005, American journal of medical genetics. Part C, Seminars in medical genetics.

[18]  H Snowden,et al.  AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K , 2010, Oncogene.

[19]  B. Jiang,et al.  Endothelial p70 S6 kinase 1 in regulating tumor angiogenesis. , 2008, Cancer research.

[20]  R. Abraham,et al.  Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2. , 2010, Cancer research.

[21]  W. Weichert,et al.  Specific inhibition of AKT2 by RNA interference results in reduction of ovarian cancer cell proliferation: increased expression of AKT in advanced ovarian cancer. , 2007, Cancer letters.

[22]  C. Mahaffey,et al.  A novel Akt3 mutation associated with enhanced kinase activity and seizure susceptibility in mice. , 2011, Human molecular genetics.

[23]  L. Mayo,et al.  A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[24]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[25]  C. Fritz,et al.  Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy. , 2010, Current opinion in chemical biology.

[26]  Alfonso Bellacosa,et al.  AKT plays a central role in tumorigenesis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[27]  D. Marsh,et al.  Rapamycin treatment for a child with germline PTEN mutation , 2008, Nature Clinical Practice Oncology.

[28]  Kyucheol Cho,et al.  Frequent monoallelic deletion of PTEN and its reciprocal associatioin with PIK3CA amplification in gastric carcinoma , 2003, International journal of cancer.

[29]  E17K substitution in AKT1 in prostate cancer , 2010, British Journal of Cancer.

[30]  T. Ludwig,et al.  Role for Akt3/Protein Kinase Bγ in Attainment of Normal Brain Size , 2005, Molecular and Cellular Biology.

[31]  Alfonso Bellacosa,et al.  Epithelial–mesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways , 2005, Oncogene.

[32]  C. Amos,et al.  Chemopreventive efficacy of rapamycin on Peutz-Jeghers syndrome in a mouse model. , 2009, Cancer letters.

[33]  Ji Luo,et al.  The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling. , 2010, Cancer research.

[34]  J. Cheng,et al.  Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas , 1998, Molecular carcinogenesis.

[35]  P. Vogt,et al.  Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[36]  I. Jonassen,et al.  Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation , 2009, Proceedings of the National Academy of Sciences.

[37]  J. Downward.  PI 3-kinase, Akt and cell survival. , 2004, Seminars in cell & developmental biology.

[38]  C. Amos,et al.  Suppression of Peutz-Jeghers Polyposis by Targeting Mammalian Target of Rapamycin Signaling , 2008, Clinical Cancer Research.

[39]  M. Milella,et al.  The mTOR pathway: a new target in cancer therapy. , 2010, Current cancer drug targets.

[40]  K. Aldape,et al.  PTEN, NHERF1 and PHLPP form a tumor suppressor network that is disabled in glioblastoma , 2011, Oncogene.

[41]  J. Sampson.  Therapeutic targeting of mTOR in tuberous sclerosis. , 2009, Biochemical Society transactions.

[42]  J. Testa,et al.  Frequent activation of AKT2 kinase in human pancreatic carcinomas , 2002, Journal of cellular biochemistry.

[43]  S. Orsulic,et al.  Mouse models of cancer. , 2011, Annual review of pathology.

[44]  C. Johannessen,et al.  TORC1 Is Essential for NF1-Associated Malignancies , 2008, Current Biology.

[45]  M.-H. Lee,et al.  Roles of p53, Myc and HIF-1 in Regulating Glycolysis — the Seventh Hallmark of Cancer , 2008, Cellular and Molecular Life Sciences.

[46]  J. Cheng,et al.  Identification of Akt Interaction Protein PHF20/TZP That Transcriptionally Regulates p53* , 2012, The Journal of Biological Chemistry.

[47]  V. P. Collins,et al.  1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas , 2008, Oncogene.

[48]  N. Rosen,et al.  Akt Forms an Intracellular Complex with Heat Shock Protein 90 (Hsp90) and Cdc37 and Is Destabilized by Inhibitors of Hsp90 Function* , 2002, The Journal of Biological Chemistry.

[49]  H. Weiss,et al.  Loss of PHLPP expression in colon cancer: Role in proliferation and tumorigenesis , 2008, Oncogene.

[50]  V. Velculescu,et al.  Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. , 2009, The American journal of pathology.

[51]  J. Woodgett,et al.  Unravelling the activation mechanisms of protein kinase B/Akt , 2003, FEBS letters.

[52]  C. Croce,et al.  MicroRNAs in the pathogenesis of cancer. , 2011, Seminars in oncology.

[53]  C. Thompson,et al.  Akt-dependent transformation: there is more to growth than just surviving , 2005, Oncogene.

[54]  I. Shiojima,et al.  Role of Akt Signaling in Vascular Homeostasis and Angiogenesis , 2002, Circulation research.

[55]  I. Barroso,et al.  An Activating Mutation of AKT2 and Human Hypoglycemia , 2011, Science.

[56]  T. de Ravel,et al.  Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1. , 2009, The Lancet. Oncology.

[57]  S. Baker,et al.  PTEN and the PI3-kinase pathway in cancer. , 2009, Annual review of pathology.

[58]  M. Oka,et al.  Analysis of DNA copy number aberrations in hepatitis C virus-associated hepatocellular carcinomas by conventional CGH and array CGH , 2004, Modern Pathology.

[59]  Cristina M. Pinto,et al.  Retracted: Frequent genetic and biochemical alterations of the PI 3‐K/AKT/PTEN pathway in head and neck squamous cell carcinoma , 2005, International journal of cancer.

[60]  Joe W. Gray,et al.  PIK3CA is implicated as an oncogene in ovarian cancer , 1999, Nature Genetics.

[61]  M. Belvin,et al.  Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3′ Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models , 2010, Clinical Cancer Research.

[62]  G. Mills,et al.  A novel AKT3 mutation in melanoma tumours and cell lines , 2008, British Journal of Cancer.

[63]  G. Lyons,et al.  Akt2 mRNA is highly expressed in embryonic brown fat and the AKT2 kinase is activated by insulin , 1998, Oncogene.

[64]  R. Pearson,et al.  A specific role for AKT3 in the genesis of ovarian cancer through modulation of G(2)-M phase transition. , 2006, Cancer research.

[65]  J. Cheng,et al.  Deregulated Akt3 Activity Promotes Development of Malignant Melanoma , 2004, Cancer Research.

[66]  P. Pandolfi,et al.  Does the ribosome translate cancer? , 2003, Nature Reviews Cancer.

[67]  Yu Huang,et al.  MicroRNA-21 promotes the cell proliferation, invasion and migration abilities in ovarian epithelial carcinomas through inhibiting the expression of PTEN protein. , 2010, International journal of molecular medicine.

[68]  Yong Liao,et al.  HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation , 2001, Nature Cell Biology.

[69]  Mallika Singh,et al.  Using Genetically Engineered Mouse Models of Cancer to Aid Drug Development: An Industry Perspective , 2006, Clinical Cancer Research.

[70]  E. Henske,et al.  Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease , 2005, Oncogene.

[71]  Charis Eng,et al.  PTEN: One Gene, Many Syndromes , 2003, Human mutation.

[72]  J. Cheng,et al.  AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[73]  K. Kaestner,et al.  Insulin Resistance and a Diabetes Mellitus-Like Syndrome in Mice Lacking the Protein Kinase Akt2 (PKBβ) , 2001 .

[74]  Peter J Houghton,et al.  Lost in translation: dysregulation of cap-dependent translation and cancer. , 2004, Cancer cell.

[75]  Wei Liu,et al.  Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer , 2012, BMC Cancer.

[76]  R. Srinivasan,et al.  Targeted therapeutic strategies for the management of renal cell carcinoma , 2012, Current opinion in oncology.

[77]  Yves Pommier,et al.  Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks , 2004, Oncogene.

[78]  J. Cheng,et al.  Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas , 1995, International journal of cancer.

[79]  A. Knudson,et al.  National Cancer Institute Workshop Report: the phakomatoses revisited. , 2000, Journal of the National Cancer Institute.

[80]  Chin-Lee Wu,et al.  mTOR and HIF-1α-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome , 2009, Proceedings of the National Academy of Sciences.

[81]  M. Birnbaum,et al.  Akt1/PKBα Is Required for Normal Growth but Dispensable for Maintenance of Glucose Homeostasis in Mice* , 2001, The Journal of Biological Chemistry.

[82]  L. Biesecker,et al.  Proteus syndrome: Misdiagnosis with PTEN mutations , 2003, American journal of medical genetics. Part A.

[83]  M. Knowles,et al.  Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms , 2008, Human molecular genetics.

[84]  Nahum Sonenberg,et al.  The Akt of translational control , 2005, Oncogene.

[85]  B. Jiang,et al.  P70S6K 1 regulation of angiogenesis through VEGF and HIF-1alpha expression. , 2010, Biochemical and biophysical research communications.

[86]  I. Campbell,et al.  The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. , 2001, Cancer research.

[87]  W. Linehan,et al.  Molecular diagnosis and therapy of kidney cancer. , 2010, Annual review of medicine.

[88]  B. Shalmon,et al.  AKT1 pleckstrin homology domain E17K activating mutation in endometrial carcinoma. , 2010, Gynecologic oncology.

[89]  C. Eng,et al.  Cowden syndrome-affected patients with PTEN promoter mutations demonstrate abnormal protein translation. , 2007, American journal of human genetics.

[90]  F. Kikkawa,et al.  Fibronectin activates matrix metalloproteinase-9 secretion via the MEK1-MAPK and the PI3K-Akt pathways in ovarian cancer cells , 2004, Clinical & Experimental Metastasis.

[91]  B. Jiang,et al.  MiR-128 Inhibits Tumor Growth and Angiogenesis by Targeting p70S6K1 , 2012, PloS one.

[92]  Spyro Mousses,et al.  A transforming mutation in the pleckstrin homology domain of AKT1 in cancer , 2007, Nature.

[93]  Jun-Ping Liu.  Studies of the molecular mechanisms in the regulation of telomerase activity , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[94]  M. Ohh,et al.  Differential Dependence of Hypoxia-inducible Factors 1α and 2α on mTORC1 and mTORC2* , 2008, Journal of Biological Chemistry.

[95]  Martha E. Zeeman,et al.  Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progression. , 2011, Cancer cell.

[96]  Maria K. Lehtinen,et al.  Somatic Activation of AKT3 Causes Hemispheric Developmental Brain Malformations , 2012, Neuron.

[97]  Qing Xu,et al.  MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis , 2011, Nucleic acids research.

[98]  B. Jiang,et al.  AKT signaling in regulating angiogenesis. , 2008, Current cancer drug targets.